WJPMR, 2026, 12(11), 14-25

Review Article

WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.wjpmr.com

Impact Factor: 7.533

ISSN (O): 2455-3301

ISSN (P): 3051-2557

Coden USA: WJPMBB

IAFA E-5 CELL REPAIR OIL: A SCIENTIFIC REVIEW OF ITS POLYHERBAL COMPOSITION, SKIN BARRIER–SUPPORTIVE MECHANISMS AND CLINICAL APPLICATIONS

Gupta Sahil[1]*

[1]CEO & Founder, Institute of Applied Food Allergy® (IAFA), IAFA Ayurveda, Gohana, India.

***Corresponding Author: Gupta Sahil**

CEO & Founder, Institute of Applied Food Allergy® (IAFA), IAFA Ayurveda, Gohana, India.

DOI: https://doi.org/10.5281/zenodo.23804657

How to cite this Article: Gupta Sahil[1]* (2026). Iafa E-5 Cell Repair Oil: A Scientific Review Of Its Polyherbal Composition, Skin Barrier–Supportive Mechanisms And Clinical Applications. World Journal of Pharmaceutical and Medical Research, 12(11), 14–25.

This work is licensed under Creative Commons Attribution 4.0 International license.

Article Received on 22/09/2026 **Article Revised on 12/10/2026** **Article Published on 01/11/2026**

ABSTRACT

Background: Chronic dermatological disorders, including atopic dermatitis, eczema, allergic dermatitis, pruritic disorders, seborrheic dermatitis, xerosis, fissuring, and other inflammatory skin conditions, are frequently associated with epidermal barrier dysfunction, persistent inflammation, itching, oxidative stress, microbial colonization, and impaired tissue repair. Allergic skin disorders may additionally involve mast-cell activation, histamine release, and immune dysregulation. These challenges have increased interest in herbal topical formulations that may simultaneously support skin hydration, barrier restoration, inflammatory modulation, antimicrobial protection, and tissue repair. **Aim:** To comprehensively review the Ayurvedic herbs, phytochemical composition, pharmacological activities, dermatological relevance, and available clinical evidence concerning IAFA E-5 Cell Repair Oil. **Methods:** A narrative evidence review was conducted using literature retrieved from PubMed/MEDLINE, Google Scholar, peer-reviewed journals, Ayurvedic classical literature, AYUSH-related resources, and the official IAFA product and clinical repository. Literature concerning IAFA E-5 Cell Repair Oil and its constituent herbs, i.e., *Pongamia pinnata, Albizia lebbeck, Berberis aristata, Cassia fistula, and Cocos nucifera*, was evaluated with particular emphasis on anti-inflammatory, antiallergic, antimicrobial, antioxidant, wound-healing, and skin barrier-supportive activities. **Results:** IAFA E-5 Cell Repair Oil combines four herbal extracts with coconut oil as the base. *Pongamia pinnata* demonstrates anti-inflammatory, antimicrobial, antioxidant, and wound-healing potential, while *Albizia lebbeck* exhibits antiallergic, mast-cell-stabilizing, antihistaminic, and anti-inflammatory activities relevant to allergic and pruritic skin disorders. Berberis aristata, particularly through berberine and related alkaloids, demonstrates antimicrobial and anti-inflammatory potential, whereas Cassia fistula exhibits antioxidant, antimicrobial, anti-inflammatory, and wound-healing properties. Coconut oil contributes emollient and skin-barrier-supportive effects, including evidence from clinical studies in atopic dermatitis. Formulation-specific IAFA clinical observations report use of E-5 in atopic dermatitis, eczema, seborrheic dermatitis, dyshidrotic eczema, and other allergic/inflammatory skin presentations. However, these reports commonly involve concomitant Ayurvedic medicines, dietary interventions, and other topical therapies. **Conclusion:** IAFA E-5 Cell Repair Oil demonstrates a multidimensional profile relevant to allergic, inflammatory, pruritic, dry, and barrier-impaired skin conditions. Its constituent herbs exhibit various pharmacological activities, while coconut oil supports moisturization and barrier restoration. Nevertheless, formulation-specific evidence remains predominantly observational. Randomized controlled trials, standardized phytochemical characterization, objective barrier-function studies, and long-term safety assessments are required to establish its efficacy and clinical positioning.

KEYWORDS: IAFA E-5 Cell Repair Oil; allergic skin disorders; allergic dermatitis; atopic dermatitis; eczema; pruritus; skin barrier; wound healing; phytochemistry; herbal medicine; integrative dermatology; Karanj; *Pongamia pinnata*; Shirisha; *Albizia lebbeck*; Darvi; *Berberis aristata*; *Aragwadha*; *Cassia fistula*; *Cocos nucifera*; eczema; atopic dermatitis; skin barrier; wound healing; phytochemistry; herbal medicine; integrative dermatology.

1. INTRODUCTION

The skin is the largest organ of the human body and acts as an important protective barrier between the body and the external environment. In addition to providing physical protection, it performs important roles in immunity, sensation, temperature regulation, prevention of water loss, and protection against microorganisms, allergens, chemicals, and other environmental factors. The epidermal barrier, particularly the outermost layer of the skin known as the stratum corneum, plays a central role in maintaining skin health. It helps retain water within the skin while limiting the entry of irritants, allergens, and microorganisms. Proper organization of skin cells, lipids, proteins, and natural moisturizing factors is therefore essential for maintaining normal skin barrier function.

The skin barrier is not only a physical protective layer but also an active part of the skin's immune system. Keratinocytes and other skin cells can recognize harmful stimuli and release inflammatory mediators when the barrier is damaged. Important proteins involved in epidermal structure and hydration, including filaggrin, involucrin, and loricrin, help maintain normal barrier function. Skin lipids such as ceramides, cholesterol, and fatty acids are also essential for reducing excessive water loss and maintaining the structure of the epidermis. Disturbance of these components can increase transepidermal water loss (TEWL), reduce skin hydration, and make the skin more sensitive to allergens, irritants, and microbial infection.

Barrier dysfunction is particularly important in chronic inflammatory and allergic skin disorders. Atopic dermatitis is a well-known example in which impaired barrier function and immune dysregulation interact with each other. Reduced barrier integrity allows greater penetration of allergens and irritants into the skin, while inflammatory cytokines can further disturb epidermal differentiation and barrier proteins. This creates a self-perpetuating cycle in which barrier damage promotes inflammation and inflammation further weakens the barrier. Similar interactions between barrier dysfunction and inflammation are also relevant to eczema, allergic contact dermatitis, irritant dermatitis, xerosis, and other chronic inflammatory skin conditions.

The skin microbiome is another important factor in maintaining healthy skin. A balanced population of microorganisms normally lives on the skin and interacts with epidermal cells and the immune system. In barrier-impaired inflammatory conditions, changes in the skin microbiome may occur, including increased colonization by Staphylococcus aureus in atopic dermatitis. Such microbial changes may increase inflammation and worsen skin-barrier damage. At the same time, a damaged skin barrier makes the skin more susceptible to microbial colonization. Thus, barrier integrity, inflammation, immune responses, and skin microbiome are closely connected in several chronic dermatological disorders. Pruritus is another major feature of many inflammatory and allergic skin disorders. Persistent itching often leads to repeated scratching, which produces further mechanical damage to the epidermis. This creates an itch–scratch cycle in which itching causes scratching, scratching damages the skin barrier, and barrier damage further increases inflammation and itching. Therefore, effective long-term management of chronic skin disorders requires more than temporary relief of symptoms. Maintenance of skin hydration, restoration of barrier function, control of inflammation, reduction of microbial complications, and prevention of repeated skin injury are important therapeutic goals.

This has increased interest in topical preparations that can provide multiple supportive effects at the same time. Emollients and barrier-supportive preparations are widely used in the management of dry skin, eczema, and atopic dermatitis because they help improve hydration, reduce water loss, soften dry and cracked skin, and support recovery of the epidermal barrier. Coconut oil is of particular interest because, in addition to its traditional use as a skin-conditioning oil, it has been investigated clinically for barrier-related skin disorders. In a randomized double-blind clinical trial involving 117 children with mild-to-moderate atopic dermatitis, topical virgin coconut oil produced improvement in disease severity and objective measures of skin barrier function, including TEWL and skin capacitance, compared with mineral oil. These findings support the role of coconut oil as a useful emollient and barrier-supportive topical ingredient, although the findings cannot be directly considered evidence for the efficacy of every formulation containing coconut oil. Ayurveda provides a broader traditional framework for understanding skin health and skin disorders. Classical Ayurvedic literature describes a wide range of dermatological conditions under *Kushtha*, *Kshudra Kushtha*, *Vicharchika*, *Kandu*, and other forms of *Twak Vikara*. These conditions may present with itching, dryness, roughness, scaling, discoloration, inflammation, discharge, thickening, fissuring, and recurrent lesions. Although classical Ayurvedic disease categories should not be considered exact equivalents of modern dermatological diagnoses, their descriptions provide an important traditional work for understanding different patterns of skin disturbance.

According to Ayurvedic principles, the development and clinical presentation of skin disorders may involve different combinations of *Dosha*, *Dushya*, *Agni*, *Srotas*, *Rakta*, and *Twak*. *Vata* involvement is commonly associated with dryness, roughness, fissuring, scaling, and chronicity. *Pitta* involvement may be expressed through redness, inflammation, burning, warmth, or discharge, while *Kapha* may contribute to itching, thickening, heaviness, exudation, and persistent lesions. *Rakta* is also given an important place in the classical understanding of several skin disorders. Therefore, Ayurvedic management may include both internal and external therapies selected according to the patient's

clinical presentation, *Dosha* involvement, disease stage, and tissue condition.

External therapies such as *Taila*, *Lepa*, *Malahara*, and *Ghrita* have traditionally been used in Ayurvedic management of *Twak Vikara*. *Taila* preparations are particularly relevant when dryness, roughness, cracking, and loss of skin softness are present because their *Snigdha* and *Snehana* properties help provide lubrication and nourishment to the skin. Depending on the herbs used, topical Ayurvedic preparations may also provide *Kandughna*, *Shothahara*, *Krimighna*, *Kushtaghna*, *Ropana*, and *Tvachya* actions. These traditional actions can be studied using modern parameters such as reduction in inflammation and itching, antimicrobial activity, antioxidant activity, improvement in hydration, reduction in TEWL, and support of tissue repair. However, such comparisons should be made carefully because traditional Ayurvedic concepts and modern molecular mechanisms are not always directly equivalent.

IAFA E-5 Cell Repair Oil is a proprietary Ayurvedic polyherbal topical formulation developed *using Karanj (Pongamia glabra* Vent.; synonym *Pongamia pinnata* (L.) Pierre), *Shirisha (Albizia lebbeck* (L.) Benth.), *Darvi (Berberis aristata* DC.), *Aragwadha (Cassia fistula* L.), and coconut oil (*Cocos nucifera* L.). The formulation contains 2 g of each *of the Karanj* seed extract, *Shirisha* bark extract, *Darvi* bark extract, and *Aragwadha* seed extract incorporated into a coconut oil base. The product is intended for external application and is described for uses including eczema/atopic dermatitis, hyperkeratosis, skin-damage repair, dryness, cracks, wound healing, and diaper rash.

The formulation contains herbs with different but potentially complementary activities. *Pongamia pinnata* has been investigated for anti-inflammatory, antimicrobial, antioxidant, and wound-healing effects. *Albizia lebbeck* is particularly relevant to allergic and itching-related skin disorders because experimental studies have reported antiallergic, antihistaminic, and mast-cell-stabilizing activities. *Berberis aristata* contains important isoquinoline alkaloids, particularly berberine, and has been studied for antimicrobial, anti-inflammatory, antioxidant, and wound-healing effects. *Cassia fistula* has demonstrated antioxidant, antimicrobial, anti-inflammatory, and wound-healing activities in experimental studies. Coconut oil provides an emollient base and contributes to skin hydration and barrier support.

The combination of these ingredients provides a rationale for studying E-5 Cell Repair Oil in skin conditions in which several processes occur together, including barrier disruption, dryness, inflammation, itching, allergic reactions, microbial involvement, oxidative stress, and impaired tissue repair. This is particularly relevant to chronic allergic and inflammatory skin conditions such as atopic dermatitis, eczema, allergic dermatitis, and other pruritic or barrier-impaired dermatoses.

However, evidence for the individual ingredients should not automatically be considered evidence for the complete E-5 formulation. The biological activity of a finished herbal preparation depends on the plant part used, extraction method, concentration of active constituents, formulation process, stability, skin penetration, and possible interactions between ingredients. Similarly, improvement reported in a clinical case in which E-5 is used together with internal Ayurvedic medicines, dietary changes, or other topical treatments cannot establish the independent effect of E-5.

Therefore, a systematic evaluation of both traditional knowledge and modern scientific evidence is important for understanding the therapeutic potential of IAFA E-5 Cell Repair Oil. The present review examines its Ayurvedic rationale, herbal composition, phytochemical constituents, pharmacological activities, relevance to allergic and inflammatory skin disorders, skin-barrier and tissue-repair potential, available clinical observations, safety considerations, and current evidence gaps. Particular emphasis is placed on distinguishing evidence obtained from individual ingredients from evidence specifically generated for the finished E-5 formulation.

2. Review Methodology

2.1 Literature Search Strategy

A comprehensive narrative literature search was performed using PubMed/MEDLINE, Google Scholar, peer-reviewed scientific journals, Ayurvedic classical literature, AYUSH-related resources, and official IAFA product and clinical webpages.

The following combinations of keywords were used

- IAFA E-5 Cell Repair Oil
- E-5 Cell Repair Oil
- *Pongamia glabra*
- *Pongamia pinnata*
- *Karanj*
- *Albizia lebbeck*
- *Shirisha*
- *Berberis aristata*
- *Darvi*
- Berberine
- Cassia fistula
- Aragwadha
- Cocos nucifera
- coconut oil
- eczema
- atopic dermatitis
- seborrheic dermatitis
- skin barrier
- wound healing
- anti-inflammatory
- antimicrobial

- antiallergic
- mast-cell stabilization
- antioxidant
- phytochemistry
- *Ayurveda*
- *Twak Vikara*
- *Vicharchika*
- *Kushtha.*

Reference lists of relevant reviews and experimental publications were additionally reviewed to identify important primary studies.

2.2 Inclusion Criteria

Studies were considered when they included one or more of the following.

- Peer-reviewed pharmacological studies
- Phytochemical investigations
- In Vitro Studies
- Animal studies
- Human clinical trials involving constituent ingredients
- Case reports involving IAFA E-5 Cell Repair Oil
- Ayurvedic classical references
- Systematic and narrative reviews relevant to the constituent herbs or topical dermatology.

2.3 Exclusion Criteria

The following were excluded:

- Duplicate publications
- Non-scientific promotional material when used as evidence of efficacy
- Unverifiable claims
- Studies without adequate methodological information
- Evidence from unrelated herbal species when formulation-specific inference was not justified.

2.4 Data Extraction

The following information was extracted:

- Botanical identity
- Plant part used
- Quantity in formulation
- Ayurvedic therapeutic attributes
- Major phytochemicals
- Pharmacological activities
- Dermatological relevance
- Formulation-specific clinical observations
- Safety information
- Limitations of available evidence

3. Composition of IAFA E-5 Cell Repair Oil

IAFA E-5 Cell Repair Oil is a five-component herbal oil preparation.

Table 1: Composition of IAFA E-5 Cell Repair Oil.

Ingredient	Botanical Name	Family	Part Used	Quantity
Karanj	*Pongamia glabra* Vent. (*Pongamia pinnata* (L.) Pierre)	Fabaceae	Seed extract	2 g
Shirisha	*Albizia lebbeck* (L.) Benth.	Fabaceae	Bark extract	2 g
Darvi	*Berberis aristata* DC.	Berberidaceae	Bark extract	2 g
Aragwadha	*Cassia fistula* L.	Fabaceae	Seed extract	2 g
Coconut oil	*Cocos nucifera* L.	Arecaceae	Oil	100 mL

4. Ayurvedic pharmacodynamic basis of IAFA E-5 Cell Repair Oil

Ayurveda considers Twak (skin) an important component of the body that reflects the state of *Dosha*, *Dhatu*, *Agni*, and overall physiological balance. Classical Ayurvedic literature describes a wide range of skin disorders under *Kushtha*, *Kshudra Kushtha*, *Vicharchika*, *Kandu*, and other forms of *Twak Vikara*. These conditions may present with different combinations of *Kandu* (itching), *Rukshata* (dryness), *Daha* (burning), *Raga* or *Vaivarnya* (discoloration), *Shotha* (swelling/inflammation), *Pidika* (lesions), *Srava* (discharge), and *Twak Vaivarnya*. The clinical presentation may vary according to the predominant *Dosha*, the tissues involved, chronicity, and stage of the disease.

From an Ayurvedic perspective, *Vata*, *Pitta*, and *Kapha* may contribute differently to the development and persistence of skin disorders. *Vata* is associated with *Rukshata* (dryness), *Parushata* (roughness), *Khara* or fissured skin, scaling, and chronicity. *Pitta* is associated with *Daha* (burning), *Raga* (redness), *Ushnata* (heat), inflammation, and certain inflammatory or exudative manifestations. *Kapha* may contribute to *Kandu* (itching), *Snigdhata*, thickening, heaviness, excessive discharge, and persistent lesions. *Rakta* is also considered important in the pathogenesis of several skin disorders, particularly those presenting with redness, inflammation, burning, discoloration, and recurrent skin manifestations. Therefore, the Ayurvedic approach to skin disease is not limited to treating a local lesion but considers the underlying *Dosha* and *Dushya* involvement.

The concept of *Kandu* is particularly relevant to allergic and inflammatory skin disorders. Persistent itching may lead to repeated scratching and further damage to the skin. Ayurvedic management therefore gives importance to therapies possessing *Kandughna* properties, particularly when itching is a prominent clinical feature. Similarly, *Shothahara* and *Daha-Shamana* approaches may be considered when inflammation, redness,

swelling, or burning is present, while *Krimighna* measures may be relevant when microbial involvement is suspected.

The selection of external therapy is also based on the properties of the formulation and the condition of the skin. *Taila* is traditionally used for its *Snigdha* and *Snehana* properties and is particularly relevant in conditions associated with dryness, roughness, fissuring, and loss of normal skin softness. Depending on the herbs used, medicated oils may additionally provide *Kandughna*, *Kushtaghna*, *Krimighna*, *Shothahara*, *Ropana*, and *Tvachya* actions. In this context, topical therapy can provide local support while systemic Ayurvedic management take care of broader *Dosha* and *Dushya* involvement where clinically indicated.

IAFA E-5 Cell Repair Oil follows this general therapeutic principle by combining four medicinal plant extracts with a coconut-oil base. The formulation contains *Karanj*, *Shirisha*, *Darvi*, and *Aragwadha* along with *Cocos nucifera* oil. The ingredients have traditionally recognized relevance to skin disorders and possess different Ayurvedic properties that may complement one another in topical application.

Table 2: Ayurvedic Therapeutic Orientation of the Ingredients of IAFA E-5 Cell Repair Oil.

Ingredient	Ayurvedic Therapeutic Properties	Uses in Topical Skin Disorders
Karanj (Pongamia pinnata)	*Kushtaghna, Kandughna, Krimighna, Shothahara*	Supports management of itching, skin disorders, microbial involvement, and inflammatory changes
Shirisha (Albizia lebbeck)	*Vishaghna, Kandughna, Shothahara*	Traditionally useful in allergic manifestations, itching, and inflammatory skin reactions
Darvi (Berberis aristata)	*Kushtaghna, Krimighna, Shothahara;* traditionally used in *Rakta*-related disorders	Supports management of inflammatory and microbial skin conditions
Aragwadha (Cassia fistula)	*Kushtaghna, Shothahara, Ropana, Tvachya*	Traditionally useful for inflammatory skin disorders and restoration of damaged skin
Coconut oil (Cocos nucifera)	*Snigdha, Snehana, Tvachya, Ropana*	Provides lubrication, nourishment, softness, and support in dry and damaged skin

The Ayurvedic importance of the formulation can therefore be understood through a combination of *Snehana*, *Twak-Poshana*, *Kandughna*, *Shothahara*, *Kushtaghna*, *Krimighna*, and *Ropana* actions. The oil base primarily helps with dryness and loss of skin softness, while the herbal ingredients provide additional support for itching, inflammation, microbial involvement, allergic manifestations, and tissue repair.

In allergic and inflammatory skin conditions, this combination is particularly relevant because itching, inflammation, dryness, scratching, and barrier damage may occur together. From an Ayurvedic perspective, such presentations may involve varying contributions of *Vata*, *Pitta*, *Kapha*, and *Rakta* depending on the individual clinical pattern. Thus, E-5 oil may be considered as an external supportive formulation whose selection should be guided by the nature and stage of the skin disorder rather than by a single disease label.

Accordingly, the Ayurvedic conceptual basis of IAFA E-5 Cell Repair Oil provides a traditional therapeutic importance for its use in skin conditions characterized by dryness, itching, inflammation, allergic manifestations, microbial involvement, and impaired skin integrity, while contemporary phytochemical and pharmacological evidence can be used to further investigate the biological basis of these traditional applications.

5. Therapeutic Significance of Individual Ingredients

5.1 Karanj- *Pongamia glabra / Pongamia pinnata*

Karanj is a traditionally important Ayurvedic plant used in disorders involving skin, wounds, itching, and microbial complications. Modern literature identifies Pongamia pinnata as a source of flavonoids, Furano flavonoids, terpenoids, sterols, and fatty acids.

A major review of P. pinnata documented traditional use in skin diseases and wounds and described antioxidant, antimicrobial, and anti-inflammatory activities of different plant preparations and isolated constituents.

Experimental work has additionally demonstrated wound-healing, antimicrobial, and antioxidant activity of P. pinnata leaf extract. In a rat model, treatment was associated with improved wound contraction and tensile strength together with antimicrobial and antioxidant effects.

A recent 2026 review further summarizes potential anti-inflammatory mechanisms involving pathways including NF-κB, COX-2, iNOS, and pro-inflammatory cytokines, while emphasizing that clinical validation and standardization remain insufficient.

Table 3: Pharmacological Relevance of *Pongamia pinnata.*

Activity	Experimental Evidence	Potential Dermatological Relevance
Anti-inflammatory	Modulation of inflammatory pathways	Eczema and inflammatory dermatoses
Antimicrobial	Activity against multiple bacterial and fungal organisms	Secondary microbial involvement
Antioxidant	Reduction of oxidative damage	Chronic inflammatory skin conditions
Wound healing	Improved contraction and tissue repair in animal models	Fissures and superficial wounds
Barrier support	Lipid-rich plant constituents may support topical conditioning	Dry and damaged skin

Importantly, these studies involve specific extracts, plant parts, or isolated compounds. Their findings should not be directly interpreted as proof of equivalent activity of the exact E-5 formulation.

5.2 Shirisha- Albizia lebbeck

Albizia lebbeck is traditionally recognized for its antiallergic and *Vishaghna* properties and has attracted substantial pharmacological interest because of its mast-cell-modulating and antihistaminic effects.

A standardized *A. lebbeck* extract demonstrated mast-cell-stabilizing activity and modulation of histamine and cytokine responses in experimental models. (Pub Earlier experimental research also reported cromoglycate-like effects on sensitized mast cells and inhibition of early sensitization processes.

A recent systematic review published in 2026 identified 17 studies, including clinical and preclinical investigations, and concluded that *A. lebbeck* bark and leaves demonstrate consistent anti-inflammatory, mast-cell-stabilizing, and antihistaminic activity while emphasizing the need for further well-designed clinical trials.

Table 4: Dermatological Pharmacological Significance of *Albizia lebbeck.*

Pharmacological Activity	Mechanistic Evidence	Potential Application
Antiallergic	Modulation of mast-cell degranulation	Allergic dermatitis
Antihistaminic	Suppression of histamine-associated signaling	Pruritus
Anti-inflammatory	Modulation of inflammatory mediators	Eczema and dermatitis
Antioxidant	Free-radical scavenging	Oxidative skin stress
Immunomodulatory	Modulation of immune signaling	Chronic inflammatory dermatoses

5.3 Darvi- *Berberis aristata*

Berberis aristata, commonly known as Darvi or Indian barberry, is an important Ayurvedic medicinal plant. Its phytochemistry is characterized particularly by isoquinoline alkaloids, with berberine being one of the principal bioactive constituents. Contemporary reviews describe antimicrobial, anti-inflammatory, antioxidant, and other pharmacological activities associated with B. aristata and berberine.

The antimicrobial potential of B. aristata root bark has been experimentally demonstrated against multiple microorganisms. Of particular dermatological relevance, a study evaluating B. aristata root-bark extract in topical herbal ointments demonstrated enhanced wound contraction and epithelialization in animal wound models, with berberine and tetrahydropalmatine identified among the major phytoconstituents.

Table 5: Major Pharmacological Contributions of Berberis aristata.

Activity	Evidence	Possible Relevance
Antimicrobial	Broad-spectrum experimental activity	Microbial skin involvement
Anti-inflammatory	Berberine-associated inflammatory modulation	Dermatitis
Antioxidant	Reduction of oxidative stress	Chronic inflammation
Wound healing	Improved epithelialization and wound contraction in animal models	Skin repair
Barrier-supportive potential	Indirect through reduction of inflammation and microbial burden	Damaged skin

5.4 Aragwadha- *Cassia fistula*

Cassia fistula is a classical medicinal plant with documented traditional use and a broad pharmacological literature. Modern reviews describe antioxidant, antimicrobial, anti-inflammatory, wound-healing, and other activities.

Experimental research has demonstrated antimicrobial activity of C. fistula extracts against several bacterial and

fungal organisms. In an infected wound model, topical C. fistula leaf extract ointment improved wound closure and tissue regeneration.

A clinical study has also evaluated topical C. fistula fruit gel for cutaneous lesions of pemphigus vulgaris, providing a higher level of topical human evidence than is available for many other traditional botanicals, although this evidence cannot be extrapolated directly to E-5 because the preparation and clinical context differ.

Table 6: Pharmacological Evidence for *Cassia fistula.*

Activity	Experimental Finding	Potential Relevance
Antimicrobial	Activity against bacterial and fungal pathogens	Secondary infection
Anti-inflammatory	Rhein demonstrated suppression of inflammatory mediators	Inflammatory dermatitis
Antioxidant	Phenolic and flavonoid-rich fractions showed radical-scavenging activity	Oxidative skin damage
Wound healing	Improved wound closure and tissue regeneration	Fissures and wounds
Topical clinical evidence	Fruit gel investigated in cutaneous pemphigus lesions	Supports topical research rationale

Rhein isolated from C. fistula has demonstrated anti-inflammatory activity in animal models with reduction of inflammatory mediators including TNF-α, IL-6 and IL-1β, together with modulation of oxidative-stress pathways.

A randomized double-blind clinical trial involving 117 children with mild-to-moderate atopic dermatitis found that topical virgin coconut oil improved SCORAD, reduced transepidermal water loss, and increased skin capacitance compared with mineral oil.

5.5 Coconut Oil- *Cocos nucifera*

Coconut oil forms the lipid base of IAFA E-5 Cell Repair Oil and has an important role beyond serving merely as a vehicle. Its fatty-acid composition and emollient characteristics can contribute to reduction of dryness, improvement of skin hydration, and barrier support.

Other clinical literature supports the use of coconut-derived topical preparations for improving skin barrier function and hydration.

Table 7: Dermatological Significance of Coconut Oil.

Activity	Evidence	Clinical Relevance
Moisturization	Improved skin capacitance in clinical studies	Xerosis
Barrier repair	Reduced TEWL	Atopic dermatitis and dermatitis
Anti-inflammatory	Experimental anti-inflammatory activity	Inflamed skin
Antimicrobial	Activity against selected skin microorganisms	Secondary microbial protection
Emollient action	Lipid-based occlusive and conditioning effects	Cracked and dry skin

The role of coconut oil therefore provides a strong formulation-level reason for combining herbal extracts with an emollient lipid base.

6. Phytochemistry of IAFA E-5 Cell Repair Oil

The formulation contains phytochemically diverse Ayurvedic herbs. The major classes potentially represented include:

- Flavonoids
- Furano flavonoids
- Isoquinoline alkaloids
- Phenolic compounds
- Tannins
- Saponins
- Terpenoids
- Phytosterols
- Fatty acids
- Anthraquinone-related compounds.

Table 8: Herbs in E- 5 oil and their phytochemical Classes.

Herbs	Representative Phytochemical Groups/Compounds
Pongamia pinnata	Karanjin, pongamol, flavonoids, furanoflavonoids, terpenoids, sterols
Albizia lebbeck	Saponins, catechin, flavonoids, tannins, terpenoids
Berberis aristata	Berberine and related isoquinoline alkaloids
Cassia fistula	Rhein, chrysophanol, catechin, gallic acid, flavonoids, phenolics
Cocos nucifera	Lauric, myristic, caprylic, capric, and oleic acids, tocopherols, and phenolic compounds

Phytochemical diversity provides a biological basis for potentially simultaneous modulation of inflammation, oxidative stress, microbial burden, itching, and tissue repair.

However, an important scientific limitation must be emphasized: the presence of a phytochemical in a plant does not establish that the same compound is present at therapeutically meaningful concentrations in the finished E-5 oil. Formulation-specific quantitative phytochemical profiling is therefore an important future research requirement.

7. Proposed Synergistic Pharmacology of IAFA E-5 Cell Repair Oil

The formulation can be conceptualized as a multitarget topical preparation rather than a single-mechanism drug.

Table 9: Functional Contribution of Individual Ingredients.

Ingredient	Primary Contribution	Secondary Contribution
Karanj	Antimicrobial and anti-inflammatory	Antioxidant and wound healing
Shirisha	Antiallergic and mast-cell modulation	Anti-inflammatory and antioxidant
Darvi	Antimicrobial	Anti-inflammatory and wound healing
Aragwadha	Antioxidant and anti-inflammatory	Antimicrobial and wound healing
Coconut oil	Moisturization and barrier support	Emollient and antimicrobial support

Proposed Multidimensional Mechanisms

The formulation may theoretically act through several interconnected pathways.

1. Barrier restoration

Coconut oil provides an occlusive and emollient lipid environment that may decrease excessive water loss and improve skin hydration.

2. Inflammatory modulation

Karanj, *Shirisha*, *Darvi*, and *Aragwadha* have individually demonstrated anti-inflammatory effects in experimental systems.

3. Antiallergic activity

Albizia lebbeck has particularly strong experimental evidence for mast-cell stabilization and modulation of histamine-related pathways.

4. Antimicrobial protection

Karanj, *Darvi*, and *Aragwadha* demonstrate antimicrobial activity in experimental studies, potentially supporting skin integrity when microbial colonization accompanies inflammation.

5. Oxidative-stress reduction

Flavonoids, phenolics, and other antioxidant compounds may reduce oxidative stress associated with chronic inflammatory skin conditions.

6. Tissue repair

Experimental wound-healing evidence has been reported for Pongamia, Berberis, Cassia, and coconut oil-related preparations.

This proposed synergy should be regarded as a pharmacological hypothesis requiring formulation-level experimental validation, rather than as established proof of synergistic interaction.

8. Clinical Applications

8.1 Atopic Dermatitis and Eczema

Atopic dermatitis is characterized by epidermal barrier dysfunction, inflammation, xerosis, and pruritus. These features provide a strong theoretical rationale for an emollient, anti-inflammatory, antiallergic topical formulation.

The contribution of E-5 may be conceptualized through.

- Reduction of dryness
- Improvement of skin hydration
- Barrier support
- Reduction of inflammatory irritation
- Potential reduction of itching
- Antimicrobial support where microbial colonization contributes to disease severity.

8.2 Allergic and Pruritic Skin Disorders

The inclusion of Albizia lebbeck provides a specific pharmacological importance for allergic and pruritic presentations because experimental studies have demonstrated mast-cell stabilization and suppression of histamine-related responses. Accordingly, E-5 may be considered as a supportive external formulation in selected allergic skin conditions characterized by.

- Itching
- Erythema
- Dryness
- Irritation
- Recurrent inflammatory reactions.

8.3 Xerosis, Dryness and Skin Cracking

The coconut-oil base is particularly relevant to xerotic skin. Restoration of epidermal hydration and reduction of TEWL are important therapeutic goals in xerosis and atopic dermatitis.

8.4 Hyperkeratotic and Lichenified Skin

Chronic inflammation and repeated scratching can result in epidermal thickening and lichenification. The anti-inflammatory, emollient, and tissue-supportive properties of the formulation provide the best support.

However, E-5 should not be presented as a proven keratolytic or disease-modifying treatment unless supported by formulation-specific clinical studies.

8.5 Wound and Skin-Damage Repair

Individual ingredients provide experimental evidence supporting wound repair.

Pongamia pinnata has demonstrated enhanced wound contraction and tensile strength in animal models.

Berberis aristata root-bark formulations have also demonstrated improved epithelialization and wound contraction in experimental models.

C. fistula has demonstrated improved wound closure and tissue regeneration in infected animal wounds. These findings support biological plausibility but do not establish that the finished E-5 oil formulation is equivalent to these experimental preparations.

8.6 Seborrheic Dermatitis and Scalp Dryness

The formulation has also been used in IAFA clinical practice in patients with seborrheic dermatitis and scalp dryness. A reported case involved E-5 Cell Repair Oil along with other external and internal Ayurvedic interventions, with progressive reduction in flaking, itching, and dryness over follow-up. Because the patient received multiple interventions, the contribution attributable specifically to E-5 cannot be isolated.

9. Clinical Evidence Supporting IAFA E-5 Cell Repair Oil

Direct clinical evidence concerning the finished E-5 formulation remains limited. Available evidence identified from the IAFA clinical repository primarily comprises case reports and longitudinal clinical observations in which E-5 was used as one component of a broader Ayurvedic protocol.

Table 10: Formulation-Specific Limited Clinical Evidence.

Clinical Report	Condition	Role of E-5	Reported Outcome	Evidence Limitation
4-year-old child clinical report	Atopic dermatitis with allergic conditions	3–5 mL topical application three times daily	Reported reduction in dryness and skin symptoms	Multimodal therapy
12-year-old child clinical report	Atopic dermatitis associated with cow's milk allergy	Topical E-5 twice daily	Approximately 70% symptomatic improvement reported at first follow-up	Multiple interventions
34-year-old female clinical report	Eczema and sun allergy	E-5 applied to affected/dry scalp with coconut oil	Clinical improvement reported	Internal medicines and other topical therapies used
31-year-old female clinical report	Chronic seborrheic dermatitis	E-5 mixed with extra virgin coconut oil	Reduction in flaking, itching, and dryness	Retrospective/observational assessment
40-year-old female clinical report	Dyshidrotic eczema and onychomycosis	Longitudinal topical therapy	Improvement reported during 16-month multimodal treatment	Multiple medicines and dietary interventions
9-year-old child clinical report	Atopic dermatitis/allergic disease	E-5 as external therapy	Improvement in atopic lesions reported	Multimodal treatment

The IAFA clinical repository reports E-5 use in several atopic and inflammatory dermatological cases. For example, one pediatric report used 3-5 mL of E-5 oil three times daily as an external intervention alongside multiple internal formulations and other therapies. Another report involving a 12-year-old child described E-5 application twice daily, with approximately 70% relief of allergic rhinitis and atopic dermatitis symptoms at the first follow-up. A reported case of chronic seborrheic dermatitis documented reduction in flaking, itching, and dryness during a four-week observation period while E-5 was used together with other internal and external treatments. A 16-month longitudinal case involving dyshidrotic eczema and onychomycosis incorporated E-5 with multiple topicals and internal Ayurvedic formulations and dietary interventions.

Clinical Evidence Interpretation

Collectively, these observations indicate that E-5 Cell Repair Oil has been clinically utilized as an external component of Ayurvedic dermatological management, particularly in conditions involving:

- Atopic dermatitis
- Eczema
- Dryness and fissuring
- Seborrheic dermatitis
- Allergic skin manifestations
- Skin barrier impairment.

However, these reports cannot establish independent efficacy because.

- E-5 was commonly used alongside other medicines.
- Dietary interventions were frequently incorporated.
- Internal Ayurvedic therapies varied among patients.
- Study designs were generally uncontrolled.
- Sample sizes were small.
- Objective standardized dermatological endpoints were inconsistently reported.

- There are currently no high-quality randomized controlled trials evaluating E-5 as a standalone intervention.

Therefore, the current evidence should be described as preliminary clinical evidence rather than definitive proof of therapeutic efficacy.

10. Safety Profile

IAFA E-5 Cell Repair Oil is described by the manufacturer as a natural product intended for external use. Nevertheless, "natural" should not automatically be equated with "risk-free." Herbal extracts can produce irritation, allergic contact reactions, or sensitization in susceptible individuals.

The following precautions are therefore scientifically appropriate.

- External use only.
- Avoid contact with eyes and mucosal surfaces.
- Patch testing may be considered in individuals with highly reactive or sensitive skin.
- Discontinue application if significant burning, worsening erythema, swelling, or hypersensitivity develops.
- Application to deep, infected, heavily exudative, or bleeding wounds should be undertaken only under appropriate clinical supervision.
- Use in infants, pregnancy, and lactation should be individualized because formulation-specific safety data are limited.
- Patients with suspected bacterial, fungal, or viral infection should not delay appropriate diagnostic evaluation or evidence-based antimicrobial treatment.

The available safety literature on individual ingredients is reassuring in several experimental contexts, but this does not substitute for dedicated safety studies of the complete E-5 formulation.

11. Future Research Directions

Future investigations should move from ingredient-level plausibility toward formulation-level evidence.
Recommended research priorities

1. Phytochemical standardization

- Quantification of berberine
- Karanjin
- Pongamol
- Representative flavonoids
- Phenolic markers.

2. Formulation characterization

- Physicochemical stability
- Microbial limits
- Oxidative stability
- Viscosity
- Skin-spreadability
- Extract uniformity.

3. In vitro studies

- Keratinocyte inflammatory models
- Mast-cell degranulation
- Antimicrobial assays
- Antioxidant assays
- Cytotoxicity studies.

4. Barrier-function studies

- TEWL
- Filaggrin
- Involucrin
- Loricrin
- Ceramide-related markers.

5. Clinical trials

- E-5 versus standard emollient
- E-5 versus vehicle
- E-5 as adjunctive therapy
- Disease-specific trials in mild-to-moderate eczema.

6. Safety studies

- Repeat insult patch testing
- Irritation testing
- Sensitization studies
- Long-term dermatological safety assessment.

11. DISCUSSION

IAFA E-5 Cell Repair Oil is a proprietary Ayurvedic polyherbal topical formulation containing Karanj (*Pongamia glabra / Pongamia pinnata*), Shirisha (*Albizia lebbeck*), Darvi (*Berberis aristata*), Aragwadha (*Cassia fistula*), and coconut oil (*Cocos nucifera*). The formulation is particularly relevant to skin conditions involving dryness, itching, inflammation, allergic reactions, microbial involvement, barrier dysfunction, and impaired tissue repair.

From an Ayurvedic perspective, the formulation has various therapeutic uses through actions such as *Snehana, Twak-Poshana, Kandughna, Shothahara, Kushtaghna, Krimighna*, and *Ropana*. The coconut-oil base provides *Snigdha* and *Snehana* properties, making it relevant to dry, rough, cracked, and barrier-impaired skin, while the herbal ingredients provide additional support for itching, inflammation, allergic manifestations, microbial involvement, and tissue repair.

Modern pharmacological evidence provides biological support for several of these traditional applications. *Pongamia pinnata* has demonstrated anti-inflammatory, antimicrobial, antioxidant, and wound-healing activities. *Albizia lebbeck* is particularly relevant to allergic and pruritic disorders because experimental studies have demonstrated mast-cell-stabilizing and antihistaminic effects. *Berberis aristata*, largely through berberine and related alkaloids, demonstrates antimicrobial and anti-inflammatory potential, while *Cassia fistula* has shown

antioxidant, antimicrobial, anti-inflammatory, and wound-healing activities. Coconut oil has comparatively stronger human evidence, including randomized clinical evidence supporting improvement in skin hydration and barrier function in pediatric atopic dermatitis. The combination of these ingredients provides a multidimensional approach to skin disorders in which barrier damage, inflammation, itching, and microbial or allergic factors occur together. However, the presence of these activities in individual herbs does not establish that the finished E-5 formulation produces the same effects.

The formulation-specific clinical evidence is currently limited but encouraging. IAFA clinical reports describe the use of E-5 oil in atopic dermatitis, eczema, seborrheic dermatitis, dyshidrotic eczema, and other allergic or inflammatory skin presentations. However, E-5 was generally used along with internal Ayurvedic medicines, dietary interventions, or other topical treatments. Therefore, improvement reported in these cases cannot be attributed specifically to E-5. These reports should be regarded as preliminary clinical observations and hypothesis-generating evidence rather than proof of efficacy.

Compounds such as karanjin, pongamol, berberine, rhein, flavonoids, phenolics, and fatty acids are reported from the constituent plants; their actual concentrations in E-5 may vary according to plant material, extraction method, processing, and batch. Formulation-specific phytochemical characterization and quality-control studies are therefore necessary.

Well-designed controlled trials using standardized dermatological outcomes and objective barrier measures such as TEWL and skin hydration are required to establish its clinical efficacy and appropriate therapeutic role.

12. CONCLUSION

IAFA E-5 Cell Repair Oil is a proprietary Ayurvedic polyherbal topical formulation containing *Karanj*, *Shirisha*, *Darvi*, *Aragwadha*, and coconut oil. Its constituent ingredients demonstrate complementary anti-inflammatory, antiallergic, antimicrobial, antioxidant, wound-healing, and skin-protective activities, while coconut oil provides additional emollient and barrier-supportive effects. The formulation has an Ayurvedic basis through *Snehana, Twak-Poshana, Kandughna, Shothahara, Kushtaghna, Krimighna,* and *Ropana* actions, making it potentially relevant to dry, pruritic, allergic, inflammatory, and barrier-impaired skin conditions.

Clinical observations from IAFA indicate its use as an adjunctive topical therapy in atopic dermatitis, eczema, seborrheic dermatitis, dyshidrotic eczema, and other inflammatory or allergic skin presentations. However, these reports are predominantly observational and involve multiple concurrent interventions; therefore, they cannot establish the independent efficacy of E-5. Overall, the available evidence supports IAFA E-5 Cell Repair Oil as a promising adjunctive Ayurvedic topical formulation. Formulation-specific randomized controlled trials, quantitative phytochemical standardization, objective skin-barrier studies, and long-term safety assessments are required to establish its efficacy, optimal use, and clinical position in evidence-based integrative dermatology.

REFERENCES

1. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol, 2014; 134(6): 1527–1534. doi:10.1038/jid,2013.446.
2. Milner SM. Skin Anatomy. Eplasty, 2023; 23: QA8.
3. Brito S, Baek M, Bin BH. Skin Structure, Physiology, and Pathology in Topical and Transdermal Drug Delivery. Pharmaceutics, 2024; 16(11): 1403.
4. Al Muqarrabun LMR, Ahmat N, Ruzaina SAR, Ismail NH, Sahidin I. Medicinal uses, phytochemistry and pharmacology of Pongamia pinnata (L.) Pierre: a review. J Ethnopharmacol, 2013; 150(2): 395–420. doi:10.1016/j.jep,2013.08.041.
5. Dudhatra B, Thummar K, Vadalia J, Bhatt V. Anti-inflammatory Potential of Pongamia pinnata: A Comprehensive Review on Molecular Mechanisms and Therapeutic Implications. Antiinflamm Antiallergy Agents Med Chem, 2026. doi:10.2174/0118715230-4262262-60126161153.
6. Dwivedi D, Dwivedi M, Malviya S, Singh V. Evaluation of wound healing, antimicrobial and antioxidant potential of Pongamia pinnata in Wistar rats. J Tradit Complement Med, 2017; 7(1): 79- 85. doi:10.1016/ j.jtcme,2015.12.002.
7. Venkatesh P, Mukherjee PK, Kumar NS, et al. Anti-allergic activity of standardized extract of Albizia lebbeck with reference to catechin as a phytomarker. Immunopharmacol Immunotoxicol, 2010; 32(2): 272– 276. doi: 10. 3109/v089239_ 70903305481.
8. Tripathi RM, Sen PC, Das PK. Studies on the mechanism of action of Albizzia lebbeck, an Indian indigenous drug used in the treatment of atopic allergy. J Ethnopharmacol. 1979; 1(4): 385–396. doi:10.1016/S0378-8741 (79)80003-3.
9. Sureshmanyala S, et al. Panchashirishadi Agad: A Systematic Review of the Anti-Allergic and Immunomodulatory Potential of Albizia lebbeck. J Pharm Bioallied Sci, 2026. doi:10.4103/jpbs.Jpbs.1562.25.
10. Albizia lebbeck suppresses histamine signaling by the inhibition of histamine H1 receptor and histidine decarboxylase gene transcription. PubMed. PMID: 21782040.
11. Berberis aristata DC. (Indian barberry): Current insight into botanical, phytochemical, and pharmacological aspects, pharmacokinetics, safety

of use, and modern therapeutic applications. PubMed. PMID: 40239774.
12. Scientific validation of the antimicrobial and antiproliferative potential of Berberis aristata DC root bark, its phytoconstituents and their biosafety. PubMed. PMID: 31512002.
13. Evaluation of Wound Healing Potential of Root Bark Extract of Berberis aristata and Molecular Docking Analysis of Berberis Phytoconstituents. PubMed. PMID: 36824006.
14. Raposa B, et al. The medicinal properties of Cassia fistula L.: A review. PubMed, 2021. PMID: 3460l. 1194.
15. Duraipandiyan V, Ignacimuthu S. Antibacterial and antifungal activity of Cassia fistula L.: an ethnomedicinal plant. J Ethnopharmacol, 2007; 112(3): 590– 594. doi:10.1016/j.jep,2007.04.008.
16. Wound healing potential of Cassia fistula on infected albino rat model. PubMed. PMID: 16242721.
17. Bhalodia NR, Nariya PB, Acharya RN, Shukla VJ. In vitro antibacterial and antifungal activities of Cassia fistula Linn. fruit pulp extracts. Ayu, 2012; 33(1): 123– 129. Doi:10.4103/0974-8520.100329.
18. Anti-inflammatory activity of rhein isolated from the flowers of Cassia fistula L. and possible underlying mechanisms. PubMed, 2019. PMID: 30622412.
19. Topical application of Cassia fistula L. fruit gel in management of cutaneous lesions of pemphigus vulgaris: A double-blind, placebo-controlled clinical trial. PMC.
20. Evangelista MTP, Abad-Casintahan F, Lopez-Villafuerte L. The effect of topical virgin coconut oil on SCORAD index, transepidermal water loss, and skin capacitance in mild to moderate pediatric atopic dermatitis: a randomized, double-blind clinical trial. Int J Dermatol, 2014; 53(1): 100–108. doi:10.1111/ijd.12339.
21. Verallo-Rowell VM, Dillague KM, Syah-Tjundawan BS. Novel antibacterial and emollient effects of coconut and virgin olive oils in adult atopic dermatitis. Dermatitis, 2008; 19(6): 308– 315.
22. Varma SR, Sivaprakasam TO, Arumugam I, et al. In vitro anti-inflammatory and skin protective properties of virgin coconut oil. J Tradit Complement Med, 2019; 9(1): 5– 14. doi:10.1016/ j. jtcme,2017.06.012.
23. Cocos nucifera and glycerine after-work moisturizers for secondary prevention of hand dermatitis among fabric workers: a randomized, double-blind, cross-over trial. Sci Rep, 2024. doi:10.1038/s41598-024-72010-0.
24. IAFA Ayurveda. IAFA E-5 Cell Repair Oil-official product information and composition.
25. Institute of Applied Food Allergy. 34-Year-Old Female Patient Recovered from Eczema and Sun Allergy-clinical case report.
26. Institute of Applied Food Allergy. 4-Year-Old Child Recovered from Food Intolerance, Atopic Dermatitis, Nasal Allergy, Wheat Allergy, and Gluten Allergy-clinical case report.
27. Institute of Applied Food Allergy. 12-Year-Old Child Recovered from Cow Milk Allergy-clinical case report.
28. Institute of Applied Food Allergy. 31-Year-Old Female Patient Recovered from Chronic Seborrheic Dermatitis-clinical case report.
29. Institute of Applied Food Allergy. 40-Year-Old Female Patient Recovered from Dyshidrotic Eczema and Onychomycosis-longitudinal clinical report.
30. Institute of Applied Food Allergy. 9-Year-Old Child Recovered from Cow Milk Allergy, Atopic Dermatitis and Childhood Asthma-clinical case report.
31. Institute of Applied Food Allergy. 4-Year-Old Child Recovered from Allergic March-clinical case report.
32. Botanical Survey of India. Species Datasheet: Pongamia pinnata (L.) Pierre and taxonomic synonyms, including Pongamia glabra Vent.
33. Agnivesha, Charaka, Dridhabala. Charaka Samhita. Edited by Vaidya Jadavaji Trikamji Acharya. Varanasi: Chaukhambha Sanskrit Sansthan.
34. Vagbhata. Ashtanga Hridaya. Edited by Kunte AM, Navre KR. Varanasi: Chaukhambha Orientalia.
35. Sharma PV. Dravyaguna Vijnana. Vol. 2. Varanasi: Chaukhambha Bharati Academy.
36. Government of India, Pharmacopoeial/AYUSH resources concerning Ayurvedic identification and nomenclature of medicinal plants.